Compare Stocks: IVVD, CVAC, KURA, and FTH

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CVAC CureVac	$4.66	$4.66	$3.13 ▼ $5.72	$1.05B	1.77	992,546 shs	N/A
FTH Sensei Biotherapeutics	$34.24 -3.2%	$31.94	$7.45 ▼ $42.14	$913.98M	-0.28	283,456 shs	572,195 shs
IVVD Invivyd	$0.81 -3.0%	$0.76	$0.53 ▼ $3.07	$244.65M	0.81	4.05 million shs	3.58 million shs
KURA Kura Oncology	$11.20 -0.9%	$11.21	$7.36 ▼ $13.90	$1.01B	0.44	2.12 million shs	1.79 million shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CVAC CureVac	0.00%	0.00%	0.00%	0.00%	-12.90%
FTH Sensei Biotherapeutics	-3.19%	-5.20%	+4.49%	+92.14%	+3,423,999,900.00%
IVVD Invivyd	-2.98%	+1.00%	+8.75%	-16.97%	-36.09%
KURA Kura Oncology	-0.88%	-7.36%	-0.71%	+12.79%	+34.13%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CVAC CureVac	$4.66	$4.66	$3.13 ▼ $5.72	$1.05B	1.77	992,546 shs	N/A
FTH Sensei Biotherapeutics	$34.24 -3.2%	$31.94	$7.45 ▼ $42.14	$913.98M	-0.28	283,456 shs	572,195 shs
IVVD Invivyd	$0.81 -3.0%	$0.76	$0.53 ▼ $3.07	$244.65M	0.81	4.05 million shs	3.58 million shs
KURA Kura Oncology	$11.20 -0.9%	$11.21	$7.36 ▼ $13.90	$1.01B	0.44	2.12 million shs	1.79 million shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CVAC CureVac	0.00%	0.00%	0.00%	0.00%	-12.90%
FTH Sensei Biotherapeutics	-3.19%	-5.20%	+4.49%	+92.14%	+3,423,999,900.00%
IVVD Invivyd	-2.98%	+1.00%	+8.75%	-16.97%	-36.09%
KURA Kura Oncology	-0.88%	-7.36%	-0.71%	+12.79%	+34.13%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CVAC CureVac	1.00	Sell	N/A	N/A
FTH Sensei Biotherapeutics	2.87	Moderate Buy	$56.25	64.28% Upside
IVVD Invivyd	2.33	Hold	$8.00	893.42% Upside
KURA Kura Oncology	2.75	Moderate Buy	$25.40	126.79% Upside

Current Analyst Ratings Breakdown

Latest IVVD, CVAC, KURA, and FTH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	FTH Sensei Biotherapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$70.00
9/14/2026	FTH Sensei Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/14/2026	IVVD Invivyd	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/9/2026	FTH Sensei Biotherapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
9/8/2026	IVVD Invivyd	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/27/2026	IVVD Invivyd	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/24/2026	IVVD Invivyd	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/24/2026	KURA Kura Oncology	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$24.00
8/24/2026	KURA Kura Oncology	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$24.00
8/24/2026	KURA Kura Oncology	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/24/2026	KURA Kura Oncology	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$24.00

(Data available from 9/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CVAC CureVac	$70.74M	14.78	$0.99 per share	4.73	$3.36 per share	1.39
FTH Sensei Biotherapeutics	N/A	N/A	N/A	N/A	$14.74 per share	N/A
IVVD Invivyd	$53.43M	4.44	N/A	N/A	$1.04 per share	0.77
KURA Kura Oncology	$67.48M	14.77	N/A	N/A	$2.00 per share	5.60

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CVAC CureVac	$175.50M	$0.72	6.47	N/A	N/A	199.92%	-23.03%	-19.09%	N/A
FTH Sensei Biotherapeutics	-$21.08M	-$141.65	N/A	N/A	N/A	N/A	-1,012.17%	-175.69%	N/A
IVVD Invivyd	-$52.49M	-$0.33	N/A	N/A	N/A	-183.90%	-59.73%	-48.97%	11/5/2026 (Estimated)
KURA Kura Oncology	-$278.67M	-$3.37	N/A	N/A	N/A	-384.30%	-207.18%	-45.17%	11/3/2026 (Estimated)

Latest IVVD, CVAC, KURA, and FTH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	IVVD Invivyd	-$0.1067	-$0.14	-$0.0333	-$0.14	$14.40 million	$14.29 million
8/12/2026	Q2 2026	KURA Kura Oncology	-$0.8773	-$0.77	+$0.1073	-$0.77	$20.16 million	$20.87 million
8/4/2026	Q2 2026	FTH Sensei Biotherapeutics	-$5.0450	-$2.84	+$2.2050	-$0.62	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CVAC CureVac	N/A	N/A	N/A	N/A	N/A
FTH Sensei Biotherapeutics	N/A	N/A	N/A	N/A	N/A
IVVD Invivyd	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CVAC CureVac	0.03	3.70	3.69
FTH Sensei Biotherapeutics	N/A	19.69	19.69
IVVD Invivyd	N/A	5.87	5.87
KURA Kura Oncology	0.12	4.73	4.71

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CVAC CureVac	17.26%
FTH Sensei Biotherapeutics	10.50%
IVVD Invivyd	70.36%
KURA Kura Oncology	N/A

Insider Ownership

Company	Insider Ownership
CVAC CureVac	2.15%
FTH Sensei Biotherapeutics	7.00%
IVVD Invivyd	12.25%
KURA Kura Oncology	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CVAC CureVac	880	224.34 million	219.52 million	No Data
FTH Sensei Biotherapeutics	29	25.84 million	24.03 million	Not Optionable
IVVD Invivyd	122	294.76 million	258.65 million	Optionable
KURA Kura Oncology	260	88.96 million	82.20 million	Optionable

IVVD, CVAC, KURA, and FTH Headlines

Recent News About These Companies

Kura Oncology, Inc. (KURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 16 at 2:00 PM | seekingalpha.com

Kura Oncology, Inc. (NASDAQ:KURA) Receives Average Recommendation of "Moderate Buy" from Analysts

September 16 at 2:28 AM | americanbankingnews.com

Kura Oncology, Inc. (NASDAQ:KURA) Given Average Recommendation of "Moderate Buy" by Brokerages

September 16 at 2:28 AM | marketbeat.com

Kura spins diabetes work into a Lilly-backed biotech startup

September 9, 2026 | finance.yahoo.com

Kura Oncology Spins Out Caspian Therapeutics With $50 Million to Test Menin Inhibition as a Disease-Modifying Approach to Diabetes

September 9, 2026 | pharmexec.comP

Kura creates Lilly-backed spinout armed with $50M to advance next-gen diabetes therapy

September 9, 2026 | fiercebiotech.comF

Kura Oncology Names Jennifer Fulk CFO

September 9, 2026 | rttnews.com

Leukemia drug data suggested a different way to treat diabetes. A new biotech will test that idea

September 9, 2026 | statnews.comS

Kura Oncology launches diabetes-focused Caspian Therapeutics

September 9, 2026 | cen.acs.orgC

Kura Oncology Launches Caspian Therapeutics With $50 Million Funding

September 9, 2026 | finance.yahoo.com

Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes

September 9, 2026 | globenewswire.com

Kura Oncology Names Jennifer Fulk Chief Financial Officer

September 8, 2026 | marketwatch.com

Kura Oncology, Inc. : changements au sein de la direction, effectifs au 8 septembre 2026

September 8, 2026 | zonebourse.comZ

Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer

September 8, 2026 | globenewswire.com

Bank of New York Mellon Corp Makes New $2.83 Million Investment in Kura Oncology, Inc. $KURA

September 7, 2026 | marketbeat.com

Corient Private Wealth LP Takes Position in Kura Oncology, Inc. $KURA

September 5, 2026 | marketbeat.com

Kura Oncology (KURA) Receives a Buy from Mizuho Securities

September 4, 2026 | theglobeandmail.com

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 4, 2026 | globenewswire.com

Pale Fire Capital SE Sells 800,874 Shares of Kura Oncology, Inc. $KURA

September 3, 2026 | marketbeat.com

KURA Stock Gains 37.6% in a Month: Here's What You Need to Know

September 1, 2026 | zacks.com

Kura Oncology to Participate in Three Investor Conferences in September

September 1, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IVVD, CVAC, KURA, and FTH Company Descriptions

CureVac NASDAQ:CVAC

$4.66 0.00 (0.00%)

As of 09/15/2026

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Sensei Biotherapeutics NASDAQ:FTH

$34.24 -1.13 (-3.19%)

Closing price 09/16/2026 04:00 PM Eastern

Extended Trading

$34.20 -0.05 (-0.13%)

As of 09/16/2026 07:30 PM Eastern

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

Invivyd NASDAQ:IVVD

$0.81 -0.02 (-2.98%)

Closing price 09/16/2026 04:00 PM Eastern

Extended Trading

$0.82 +0.01 (+1.83%)

As of 05:04 AM Eastern

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

Kura Oncology NASDAQ:KURA

$11.20 -0.10 (-0.88%)

Closing price 09/16/2026 04:00 PM Eastern

Extended Trading

$11.25 +0.05 (+0.46%)

As of 05:25 AM Eastern

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IVVD, CVAC, KURA, and FTH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IVVD, CVAC, KURA, and FTH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IVVD, CVAC, KURA, and FTH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IVVD, CVAC, KURA, and FTH Company Descriptions

CureVac NASDAQ:CVAC

Sensei Biotherapeutics NASDAQ:FTH

Invivyd NASDAQ:IVVD

Kura Oncology NASDAQ:KURA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IVVD, CVAC, KURA, and FTH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IVVD, CVAC, KURA, and FTH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IVVD, CVAC, KURA, and FTH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IVVD, CVAC, KURA, and FTH Company Descriptions

CureVac NASDAQ:CVAC

Sensei Biotherapeutics NASDAQ:FTH

Invivyd NASDAQ:IVVD

Kura Oncology NASDAQ:KURA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools